- Home
- CRDF vs PIM Comparison
CRDF vs PIM Comparison
Compare CRDF & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- PIM
- Stock Information
- Founded
- CRDF 1999
- PIM 1988
- Country
- CRDF United States
- PIM United States
- Employees
- CRDF N/A
- PIM N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- PIM Finance Companies
- Sector
- CRDF Health Care
- PIM Finance
- Exchange
- CRDF Nasdaq
- PIM Nasdaq
- Market Cap
- CRDF 195.6M
- PIM 159.3M
- IPO Year
- CRDF N/A
- PIM N/A
- Fundamental
- Price
- CRDF $2.85
- PIM $3.25
- Analyst Decision
- CRDF Strong Buy
- PIM
- Analyst Count
- CRDF 4
- PIM 0
- Target Price
- CRDF $12.00
- PIM N/A
- AVG Volume (30 Days)
- CRDF 1.6M
- PIM 57.5K
- Earning Date
- CRDF 05-01-2025
- PIM 01-01-0001
- Dividend Yield
- CRDF N/A
- PIM 8.28%
- EPS Growth
- CRDF N/A
- PIM N/A
- EPS
- CRDF N/A
- PIM 0.05
- Revenue
- CRDF $683,000.00
- PIM N/A
- Revenue This Year
- CRDF N/A
- PIM N/A
- Revenue Next Year
- CRDF N/A
- PIM N/A
- P/E Ratio
- CRDF N/A
- PIM $63.80
- Revenue Growth
- CRDF 39.96
- PIM N/A
- 52 Week Low
- CRDF $2.01
- PIM $2.90
- 52 Week High
- CRDF $5.64
- PIM $3.28
- Technical
- Relative Strength Index (RSI)
- CRDF 41.85
- PIM 47.41
- Support Level
- CRDF $2.36
- PIM $3.18
- Resistance Level
- CRDF $3.04
- PIM $3.29
- Average True Range (ATR)
- CRDF 0.24
- PIM 0.05
- MACD
- CRDF 0.03
- PIM 0.00
- Stochastic Oscillator
- CRDF 56.98
- PIM 55.00
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.